Aziz Burgy
{ Bio Portrait }

With nearly two decades of experience, Aziz Burgy has been recognized by several organizations as a leading patent litigator (Top ANDA Litigator - Patexia Intelligence Report 2021; Top ANDA Litigator - Patexia 2020; World's Leading Patent Professional 2020-2021 - IAM Patent 1000; Life Sciences Star 2020 - LMG Life Sciences). Indeed, he was recently recognized in Patexia's ANDA Intelligence Report in the top 3% of the Best Performing ANDA Attorneys Representing Defendants over a four-year period.

He has served as lead counsel to clients in a multitude of venues including U.S. district courts, Patent Trial and Appeal Board (PTAB), U.S. Court of Appeals for the Federal Circuit (CAFC), U.S. Court of Federal Claims, and the U.S. International Trade Commission. Aziz’s practice focuses on the Hatch-Waxman Act, having litigated over seventy such cases in the last ten years. Although many of his cases have focused on pharmaceuticals, he has also represented clients in the banking, medical device, Internet security, robotics, software, and GPS technology industries and has handled other matters beyond patent disputes, including trademark and copyright cases.

Before attending law school, Aziz worked as a research associate at MedImmune, Inc., a leading biotechnology company. During his time there, Aziz worked on the development of a humanized monoclonal antibody (palivizumab) with activity against respiratory syncytial virus and a vaccine consisting of self-assembling, virus-like particles for the prevention of human papillomavirus (HPV) infection of the genital tract and associated cervical cancer. Aziz draws on his industry experience, advanced life sciences coursework, and his vast legal experience to provide him the technical and legal expertise necessary to succeed in scientifically complex matters.

Aziz is a frequent lecturer on U.S. intellectual property rights, with an emphasis on Hatch-Waxman issues. He has also taught classes on intellectual property at George Mason University. Not only is Aziz at the forefront of patent jurisprudence, he has also helped shape legislation related to patent laws. Specifically, Aziz has advised clients and Congress on various patent legislation matters dealing with the America Invents Act (AIA).


  • Judicial Intern to the Honorable Arthur J. Gajarsa of the U.S. Court of Appeals for the Federal Circuit

Professional Activities

  • Aziz is a member of the Maryland Bar Association, the District of Columbia Bar Association, PTAB Bar Association, the ITC Trial Lawyers Association, the Federal Circuit Bar Association, the American Intellectual Property Law Association, and the American Bar Association.
  • UNC Department of Biology Advisory Board Member


Representative matters:

  • Insys Therapeutics, Inc. v. Par Pharm., Inc., 17-cv-01078-LPS (D. Del.). Represented generic drug manufacturer, Par, in Hatch-Waxman litigation involving multiple patents directed to FDA-approved cannabinoid  (Syndros®) used to treat anorexia in people with AIDS. Secured dismissal of case based on non-infringement position resulting in Par having the ability to launch upon approval of its ANDA product.
  • Noden Pharma DAC v. Anchen Pharm., Inc., 17-cv-00728-MPT (D. Del.). Litigation defenses helped Anchen secure a favorable license to manufacture and commercialize generic version of Tekturna® 
  • Par Pharm., Inc. v. Horizon Therapeutics, LLC, IPR2015-01127 (P.T.A.B.). Represented Petitioner in review of U.S. Patent No. 8,404,215 directed to nitrogen scavenging drug (Ravicti®) resulting in invalidity of all challenged claims.
  • AstraZeneca Pharm., LP v. Sylvia Burwell, 16-cv-01336-RDM (D.D.C.). Represented intervenors Apotex and Par to successfully oppose AstraZeneca’s motion for a temporary restraining order allowing generic versions of blockbuster Crestor® to immediately enter the market. 
  • Purdue Pharm. Prods. L.P. v. Actavis Elizabeth LLC et al., 12-cv-05311-JLL (D.N.J.) (“Intermezzo”). Represented generic drug manufacturer, Par, in Hatch-Waxman litigation involving two patents directed to the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep.  The district court invalidated the two patents-in-suit at trial and the Federal Circuit affirmed on appeal.
  • Jazz Pharm., Inc. v. Par, Pharm., Inc., IPR2015-00548, -00551, & ‑00554 (P.T.A.B.). Served as lead IPR petition counsel orchestrating the drafting of multiple inter partes review petitions for three REMS patents directed to Jazz’s narcolepsy drug, Xyrem®, leading to invalidity of all claims on obvious grounds. The holding was later affirmed by the CAFC.
  • Certain Bulk Welding Wire Containers and Components Thereof and Welding Wire, 337‑TA‑686. Represented Respondent accused of infringing six patents related to bulk weld wire containers. After trial, the case resulted in Complainant dropping five patents, invalidation of one claim, and a non-infringement ruling against all accused products.  The case was affirmed on appeal to the Federal Circuit.
  • Cross Medical Prods., Inc. v. Medtronic Sofamor Danek, Inc., No. 05-1415 (Fed. Cir. Mar. 20, 2007). Represented Defendant Medtronic in a patent infringement case involving six patents directed to spinal implant technology. CAFC reversed the district court’s finding that Medtronic’s modified surgical screw infringed the claimed seat means limitation under the DOE, and affirmed the district court’s grant of summary judgment of noninfringement on a claimed anchor seat.
  • Tulip Computers Int’l v. Dell Computer Corp., 00-cv-00981-KAJ (D. Del.). Represented patentee against Dell Computer on a patent involving computer motherboard technology. Case settled for $49.5 million after one week jury trial.

* Includes matters handled prior to joining Axinn


  • Benchmark Litigation – DC Litigation Star: Intellectual Property (2020 – 2023) 
  • ANDA Litigation Intelligence Report: Best Performing ANDA Attorneys Representing Defendants (2021)
  • ANDA Litigation Intelligence Report: Top 100 Most Active ANDA Attorneys (2021)
  • ANDA Litigation Intelligence Report: Top ANDA Litigator (2020)
  • LMG Life Sciences – Life Sciences Star (2020 – 2023)
  • World's Leading Patent Professionals (2020 – 2023), IAM Patent 1000
  • Super Lawyers (2020 – 2023)


Thought Leadership


Seminars & Classes

  • "Biosimilar Biological Products," FDLI's Introduction to Biological Products, Including Vaccines, Biosimilars, Cell and Gene Therapies, and Other Advanced Therapies Course; March 8, 2023
  • Guest Lecturer, ECON327, The University of North Carolina, Chapel Hill, North Carolina; February 25, 2021
  • Guest Lecturer, ECON327, The University of North Carolina, Chapel Hill, North Carolina; February 13, 2020
  • “Harnessing the Power of Covered Business Method Patent Review,” ACI’s inaugural conference on Post-Grant PTO Proceedings; New York, NY; March 25-26th, 2015
  • “Combating Patent Trolls," Texas Bankers Association 130th Annual Meeting; Colorado Springs, CO; May 8, 2014
  • “Patent Wars: The Impact of Patent Trolls on Financial Services,” NACHA Counsel Mega Meeting; Reston, VA; October 3, 2013
  • “Patents: Industry Strategy and Response,” American Bankers Association; Washington, DC; May 17, 2013
  • “Dealing with Non-Practicing Entities,” American Bankers Association Community Bankers Council Spring Meeting; Tucson, AZ; April 28, 2013
  • “Receiving a Cease and Desist Letter from a Non-Practicing Entity: Top Ten Things to Know,” American Bankers Association; Washington, DC; January 10, 2013
  • Guest Lecturer, George Mason University, Fairfax, VA (Spring 2011, Spring 2012, Spring & Fall 2014)
  • “Protecting Assets Through Trade Secrets,” The Business of Intellectual Property Conference, Technology Council of Maryland; March 27, 2008


  • JD, magna cum laude – University of New Hampshire School of Law (2003); Editor, IDEA: The Journal of Law and Technology
  • MS, Biotechnology – Johns Hopkins University (2000)
  • BS, Biology – University of North Carolina at Chapel Hill (1996)


  • District of Columbia
  • Maryland
  • US Court of Appeals for the Federal Circuit
  • US Court of Federal Claims
  • US District Court District of Columbia
  • US District Court District of Maryland
  • US District Court Northern District of Ohio
  • US Patent and Trademark Office

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.